Valley Fever (Coccidioidomycosis) in Dogs — Management Guide

Practical, evidence-based guide to canine Valley Fever: where it occurs, how it causes disease, diagnosis, antifungal treatments (fluconazole), bone/CNS disease, monitoring and relapse risk.

Quick Overview

• What it is: Valley Fever (coccidioidomycosis) is a fungal infection caused by Coccidioides spp. that primarily affects the lungs but can spread (disseminate) to bones, joints, skin, and the nervous system.
• Who’s at risk: Dogs living in or traveling to endemic areas of the southwestern United States (especially Arizona and California’s Central Valley) are at highest risk; any breed can be infected, but some breeds show more severe or disseminated disease.
• Prognosis: Many dogs with localized pulmonary infection respond well to antifungal therapy; disseminated disease (bone, CNS, widespread) is harder to cure and has a higher relapse rate and guarded prognosis.

Where Valley Fever is endemic

Coccidioides immitis and C. posadasii are soil-dwelling fungi endemic to arid regions of the Americas. In the U.S., the highest risk areas are:

• Arizona (especially the Phoenix and Tucson areas)
• California’s San Joaquin (Central) Valley
• Parts of Nevada, New Mexico, Texas, Utah, and southern Colorado

Pathophysiology (simple explanation)

Dogs inhale microscopic fungal spores from disturbed soil. In the lung the spores convert to spherules that release endospores and provoke an inflammatory reaction. If host defenses contain the infection, disease may be limited to the lung or be subclinical. If the organism escapes local control, it can spread via the bloodstream or lymphatics to bones, joints, skin, eyes, and the central nervous system (CNS), producing granulomatous lesions.

Breed- and signalment-related risk factors

• Any age can be affected, but young adult to middle-aged dogs are commonly presented.
• No breed is absolutely protected; however, some studies and clinical experience suggest German Shepherd Dogs, Rottweilers and some large-breed dogs may be over-represented among dogs with disseminated disease. The reason is likely genetic or immune-related rather than direct exposure.
• Working, sporting, or outdoor dogs (diggers, prairie dogs, farm dogs) are at higher exposure risk.

Clinical signs: pulmonary vs disseminated disease

Pulmonary (most common):

• Cough (often chronic)
• Lethargy, reduced appetite, weight loss
• Fever (may be intermittent)
• Exercise intolerance

• Bone or joint pain, lameness, swelling (often in long bones, vertebrae)
• Draining skin lesions or nodules
• Neurologic signs (seizures, ataxia, cranial nerve deficits) when CNS infected
• Ocular signs (uveitis) when eye involved
• Widespread systemic illness, poor body condition

Diagnostic approach

Goal: document infection and define extent.

Treatment options

Overview: antifungal therapy is the cornerstone. Choice depends on disease location, severity, owner finances, and potential adverse effects.

First-line systemic azoles

• Fluconazole

• Itraconazole

Which to choose? For uncomplicated pulmonary disease either drug is acceptable. For CNS or bone involvement many clinicians prefer fluconazole for its superior penetration. For some skin, bone, or refractory disease itraconazole may be tried or combined.

Amphotericin B

• Used for life-threatening or rapidly progressive disease, or when azoles fail. Lipid formulations are preferable because they are less nephrotoxic.
• Dosing (general concepts): amphotericin B deoxycholate 0.3–1 mg/kg IV every other day, accumulating to a total dose based on protocol; lipid formulations dosed higher (e.g., 2–3 mg/kg). Close monitoring of renal function and electrolytes is mandatory.

• Surgery: debridement or excision of localized bone lesions, amputation for severe limb osteomyelitis, or removal of focal granulomas may be required in select cases.
• Pain control: NSAIDs (if kidney function normal), opioids, and physical therapy for bone/joint disease.
• Corticosteroids: avoided except in short-term use for life-threatening inflammation (e.g., severe bronchospasm or catastrophic neurologic edema) and under specialist guidance because they suppress immunity and can worsen fungal infections.

• Baseline and periodic liver enzymes (ALT, ALP) during azole therapy — typically every 2–4 weeks for the first 2 months, then every 2–3 months.
• CBC and biochemistry during amphotericin B therapy; pre- and post-infusion fluids and electrolytes.
• Watch for signs of hepatopathy (vomiting, jaundice, anorexia), which may require dose reduction or switch of agent.

Treatment duration and relapse risk

Duration

• Pulmonary, uncomplicated disease: minimum 4–6 months of therapy and often until clinical resolution plus serologic improvement (CF titer falling to low/negative); many clinicians treat at least 6 months and stop after 2–4 months beyond clinical and serologic resolution.
• Disseminated disease (bone, CNS, multi-site): typically treated for 12 months or longer; many dogs require >12 months and some need lifelong suppressive therapy.

• Serial CF titers every 6–12 weeks early in therapy; decreasing titers indicate response. Absolute timelines vary; clinical improvement can precede full serologic normalization.
• Repeat imaging (thoracic radiographs, bone radiographs, MRI) to document lesion stability or improvement; frequency depends on severity.

• Relapse is an important concern. Published case series and clinical experience report that relapse rates are higher for disseminated disease (including bone and CNS involvement) than for isolated pulmonary disease.
• Approximate figures (varies by study and case selection): many dogs with uncomplicated pulmonary disease do well long term with relapse rates <20%, while disseminated disease relapse rates can range 20–50% or higher, especially with bone or CNS involvement. Because of this, prolonged therapy and careful monitoring are essential.

Bone involvement (osteomyelitis) — special considerations

• Bones commonly affected: vertebrae, long bones, digits.
• Clinical signs: localized severe pain, reluctance to move, pathologic fractures, neurologic deficits when vertebrae involved.
• Diagnosis: bone radiographs (may show lytic lesions), bone scintigraphy to find multifocal lesions, CT or MRI, and bone biopsy for cytology/histopathology (definitive).
• Treatment: long-term systemic antifungals (often fluconazole or itraconazole), surgical debridement as indicated, pain control. Response tends to be slower than pulmonary disease; therapy is commonly 12 months or longer. Relapse is more common than for pulmonary disease.

Long-term management and monitoring

• Regular rechecks: physical exam and owner-reported clinical status every 4–8 weeks early, then every 3 months when stable.
• Serial serology: CF titers every 6–12 weeks initially; once stable and low, spacing can increase to every 3–6 months.
• Repeat imaging: thoracic radiographs at 2–3 month intervals initially until improvement; bone or CNS imaging as clinically indicated.
• Medication side-effect monitoring: routine liver enzyme checks while on azoles; renal monitoring with amphotericin.
• Consider maintenance therapy: some dogs with severe or relapsing disease will need lifelong low-dose azole therapy to suppress recurrence.

Prognosis and quality of life

• Pulmonary-only disease: generally good prognosis with appropriate therapy; many dogs return to normal activity and life expectancy.
• Disseminated disease (especially CNS and multifocal bone disease): prognosis is guarded to poor depending on severity and response to therapy. Some dogs do well with aggressive, prolonged therapy and supportive care; others experience progressive disease or repeated relapses.
• Owners should be counseled about the possibility of prolonged treatment, cost, monitoring, and potential for relapse.

Living with Valley Fever — practical daily tips

• Minimize dust exposure: keep dogs indoors during dry/dusty conditions, avoid areas with active soil disturbance (construction, digging sites), and consider wetting soil before digging or playing in high-risk areas.
• Exercise moderation: dogs with pulmonary or bone disease may need reduced activity during treatment; follow your veterinarian’s guidance.
• Medication adherence: give antifungals exactly as prescribed; missing doses may lead to treatment failure or resistance.
• Watch for side effects: report lethargy, vomiting, inappetence, jaundice, or changes in urination to your vet promptly.
• Home comfort: provide soft bedding and support for dogs with bone pain; use ramps and limit stairs for dogs with limb or spinal disease.

When to see your vet urgently

Seek immediate veterinary attention if your dog develops:

• Sudden or severe respiratory distress (marked panting, open-mouth breathing, collapse)
• New or worsening neurologic signs (seizures, weakness, sudden ataxia)
• Severe, uncontrolled pain or inability to use a limb
• Jaundice, persistent vomiting, or anorexia (possible drug toxicity)
• Any rapid swelling, draining skin lesion, or fever that doesn’t respond to therapy

Key takeaways

• Valley Fever is endemic in the southwestern U.S.; dogs that live in or travel to these regions can inhale spores and develop pulmonary or disseminated disease.
• Diagnosis combines history, imaging, and serology (ID/CF); identification of spherules on cytology/biopsy is definitive.
• Long-term antifungal therapy (fluconazole or itraconazole) is required; fluconazole is commonly used for CNS and bone because of better tissue penetration. Amphotericin B is reserved for severe or refractory cases.
• Bone and CNS involvement require longer therapy and carry a higher relapse risk; many cases need 12 months or more of treatment and close monitoring.
• Maintain close communication with your veterinarian or a veterinary internal medicine specialist for individualized management.

References and resources

• Merck Veterinary Manual: Coccidioidomycosis in dogs (MerckVetManual.com)
• Centers for Disease Control and Prevention (CDC): Coccidioidomycosis (Valley Fever)
• ACVIM consensus resources and veterinary infectious disease literature (consult your specialist or academic library for the most current consensus statements and peer-reviewed studies)

Frequently Asked Questions